METHOTREXATE SODIUM


Trade Names	ABITREXATE FOLEX FOLEX PFS METHOTREXATE LPF METHOTREXATE PRESERVATIVE FREE METHOTREXATE SODIUM METHOTREXATE SODIUM PRESERVATIVE FREE MEXATE MEXATE-AQ MEXATE-AQ PRESERVED TREXALL XATMEP
Synonyms	ADX-2191 SODIUM Abitrexate Disodium methotrexate Folex Folex pfs Methotrexate (as disodium) Methotrexate disodium Methotrexate disodium salt Methotrexate lpf Methotrexate preservative free Methotrexate sodium Methotrexate sodium preservative free Methotrexate sodium salt Methotrexate, sodium salt Mexate Mexate-aq Mexate-aq preserved Trexall Xatmep
Status
Molecule Category	Salt-form
UNII	3IG1E710ZN
EPA CompTox	DTXSID3037123
Parent Compound:	METHOTREXATE


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	DASQOOZCTWOQPA-GXKRWWSZSA-L
Smiles	CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-])cc1.[Na+].[Na+]
InChI	InChI=1S/C20H22N8O5.2Na/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30;;/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27);;/q;2*+1/p-2/t13-;;/m0../s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C20H20N8Na2O5
Molecular Weight	498.41
AlogP	0.27
Hydrogen Bond Acceptor	10.0
Hydrogen Bond Donor	5.0
Number of Rotational Bond	9.0
Polar Surface Area	210.54
Molecular species	ACID
Aromatic Rings	3.0
Heavy Atoms	33.0

Metabolites Network

visNetwork

Bioactivity

Mechanism of Action	Action	Reference
Dihydrofolate reductase inhibitor	INHIBITOR	DailyMed


Protein: Dihydrofolate reductase Description: Dihydrofolate reductase Organism : Homo sapiens P00374 ENSG00000228716

Cross References

Resources	Reference
ChEBI	50679
ChEMBL	CHEMBL3244648
FDA SRS	3IG1E710ZN
PubChem	11329481
SureChEMBL	SCHEMBL48420

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).